Safety and effectiveness of triple-drug therapy with ivermectin, diethylcarbamazine, and albendazole in reducing lymphatic filariasis prevalence and clearing circulating filarial antigens in Mombasa, Kenya
Triple therapy with IDA is safe and well-tolerated, with some mild-to-moderate and transient adverse events among LF-infected individuals. The high incidence of AEs highlights the need for safety monitoring during MDA. The significant reductions in LF antigenemia prevalence and high CFA clearance rates underscore IDA's effectiveness in reducing LF transmission, positioning it as a key strategy for eliminating LF as a public health problem by 2030.
Authors
- Elvis Kirui (ORCID: https://orcid.org/0000-0002-4981-2697)
- Wyckliff P. Omondi (ORCID: https://orcid.org/0000-0002-6011-2253)
- Christabel Khaemba (ORCID: https://orcid.org/0000-0003-0543-9920)
- Sammy M. Njenga (ORCID: https://orcid.org/0000-0001-6309-476X)
- Anastacia Guantai
- Eleni Aklillu (ORCID: https://orcid.org/0000-0002-9788-0790)
- Margaret Oluka (ORCID: https://orcid.org/0000-0002-4881-8667)
Institutions
- University of Nairobi (KE)
- Karolinska University Hospital (SE)
- Karolinska Institutet (SE)
- Kenya Medical Research Institute (KE)
- Ministry of Health (KE)
- Kenya Forest Service (KE)
Publication Details
- Journal
- Infectious Diseases of Poverty
- Published
- 2025-02-24
- DOI
- https://doi.org/10.1186/s40249-025-01282-z
- Citations
- 2
- Primary Topic
- Parasitic Diseases Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.79
Funders
- Styrelsen för Internationellt Utvecklingssamarbete
- Karolinska Institutet
- European and Developing Countries Clinical Trials Partnership